Tag: licensing
-
Audio-Brain Stimulation Shown to Reduce PTSD Symptoms
A clinical trial shows a non-invasive technique that translates and feeds back brain waves as audio tones reduces PTSD symptoms in current and former military personnel for 6 months.
-
Super High-Resolution Photo Sensor Developed
Engineers at Dartmouth College developed a sensor that captures light signals at high speed and resolution down to the level of individual photons.
-
Biotechs Partner on HPV Cancer Immunotherapies
Biotechnology companies in the U.S. and the Netherlands are collaborating on treatments for cancers caused by a type of human papillomavirus, or HPV.
-
Survey: More Research Patents, Start-Ups in 2016
A survey of universities and other institutions shows the number of patent filings and new start-up companies resulting from federally-funded research climbed in 2016.
-
Biotech, Cancer Center Partner on T-Cell Research
A developer of cancer diagnostics and treatments is collaborating with Moffitt Cancer Center to advance therapies for ovarian cancer with T-cells from the immune system.
-
Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal
Bayer AG, the global drug maker and agricultural chemical company, is partnering with a Japanese biologics enterprise to discover a series of peptides for therapies.
-
Biotech Licenses Mayo Clinic Microbiome Research
A biotechnology company developing therapies with specialized gut microbes is licensing research from the Mayo Clinic on these microbes’ effects with autoimmune diseases.
-
Alliance Exploring Microbiome on Cancer Immunotherapy
A biotechnology company and two research institutes are collaborating on a study of a proposed cancer treatment that targets the microbiome, communities of bacteria in the human body.
-
Zymeworks, Janssen in $1.45B Antibody Licensing Deal
Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets.
-
Sanofi Acquires Multiple Sclerosis Drug in $800M Deal
Drug maker Sanofi is licensing a drug candidate from Principia Biopharma Inc. designed to treat multiple sclerosis, an autoimmune condition affecting the brain and nervous system.